News & Press Releases
Filter by:
Mintz’s Trademark Practice Recognized in 2024 WTR 1000 Rankings
February 06, 2024
NEW YORK, SAN DIEGO, and WASHINGTON, DC - Mintz has been recognized in the 2024 edition of WTR 1000: The World’s Leading Trademark Professionals, marking the fourth consecutive year of acknowledgement by the World Trademark Review. This guide identifies the top trademark professionals and firms in over 80 jurisdictions worldwide. This year, WTR ranked Mintz in New York as a leading firm for “Enforcement and Litigation” and “Prosecution and Strategy.”
A Steady Litigation Year Helped Drive Big Law Revenue Gains
February 6, 2024
Managing Member Bob Bodian was quoted in American Lawyer’s Litigation Daily providing his analysis on how the last two years of intense deal work has led to a recent dry spell in M&A and capital markets activity, creating a “fertile ground” for litigation.
The FINRA Reports That May Foreshadow New AI Rules
February 6, 2024
Members Meredith Leary, David Adams, and Associate Sav Arguello co-authored an article in Law360 discussing the Financial Industry Regulatory Authority (FINRA)’s annual regulatory oversight report for 2024.
The Irony Of Taxing 401k Plans To Save Social Security
February 6, 2024
Fiduciary News spoke to Of Counsel Michelle Capezza in an article exploring the irony of taxing 401k plans to save social security in light of a recent report published by retirement researchers.
Member Cory Flashner spoke to the National Law Journal about a pivotal lawsuit brought by investor James Harper against the IRS, challenging the warrantless seizure of cryptocurrency records and questioning the third-party doctrine’s relevance to digital privacy at the 1st Circuit Court of Appeals. He explains the distinction in privacy expectations between crypto exchange data and cell phone records.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Press Contact